



### Screen, Track, Act | Optimizing Cancer Screening and Follow-Up Practices

Findings from the "**Tools to Close Cancer Screening Gaps Pilot**," Sustainment Activities & Future Directions

Lynn N. Ibekwe-Agunanna, PhD, MPH Stacey Coleman, MPH Emma Knapp, MPH, PCMH-CCE

## Speakers





**Lynn N. Ibekwe-Agunanna PhD, MPH** Assistant Professor, UT Southwestern Medical Center



**Stacey Coleman, MPH** Director of Quality Management, Coastal Family Health Center

## Today's Agenda



**Project Background** Disparity Paradox



Tools To Close Screening Gaps Pilot Overview & Findings



CHC Partner Perspective Coastal Family Health Center



Next Steps Looking Ahead & Future Planning

# **Project Background**



# Cancer screening reduces cancer morbidity and mortality.

Yet, disparities persist...



### The Disparity Paradox in Cancer Outcomes

The more preventable and treatable a cancer is...
the greater the disparities become in survival.



### The Role of Implementation Science

Closing the gap between what we know works—evidence-based interventions, practices, clinical guidelines—and what is used in practice.



# Tools To Close Screening Gaps Pilot

### **Tools to Close Cancer Screening Gaps**

**Goal:** Develop & pilot test **new tools in Azara DRVS** that may help CHCs more easily track and address care caps for patients in need of **diagnostic follow-up of an abnormal cancer screening**.



### **Tools to Close Cancer Screening Gaps**

**Goal:** Develop & pilot test **new tools in Azara DRVS** that may help CHCs more easily track and address care caps for patients in need of **diagnostic follow-up of an abnormal cancer screening**.



### **New DRVS Tools**

Abnormal follow-up measures Abnormal follow-up point-of-care alerts Open lab orders measure Screening and abnormal follow-up gap closure dashboard

### Abnormal Follow-Up Measures\* & Open Lab Orders Measure

#### Abnormal FIT Follow-Up\*

Patients aged 45-75 who have had a positive FIT/FOBT test in the last 12 months and have received Colonoscopy referral or completed Colonoscopy within 6 months of the test.

#### Cervical Cytology Abnormal Follow-Up\*

Patients who have received cervical cancer screening where the result was interpreted and indicated possible malignancy who have received the appropriate follow-up according to the results. Abnormal Breast Cancer Screening Follow-Up\*

> Female patients aged 40-75 who have had a breast cancer screening in the last 12 months with a result indicating possible malignancy and have received the appropriate follow-up according to the results.

#### Open Lab Orders (Completed Lab Volume)

Labs that were completed in the measurement period. Track completed labs by lab type. Used to monitor fluctuations in lab data coming into DRVS. Includes FIT/FOBT, Pap, and HPV labs.

\* **Requires additional mapping** Contact your Client Success Manager for cost & information

## Abnormal Cancer Screening Scorecard • Monitor Performance

Breast and Colorectal Cancer Screening and Abnormal Follow Up (i) REPORT PERIOD RENDERING PROVIDERS		Click Ga need ou		ify patients	who		\$7	
TY March 2023  V All Rendering Provid  V	• 5	<ul> <li>Set up automatic email subscription</li> </ul>						
E REPORT				CARE GAPS				
GROUPING No Grouping ~ TARGE	TS Primary	Secondary Not	t Met		REPORT FORMAT	orecard	~	
MEASURE	RESULT	TARGET	NUMERATOR	DENOMINATOR	EXCLUSIONS	GAP		
Breast Cancer Screening Ages 50-74 (CMS 125v10)	38.8%	63.0%	576	1,483	4	907	<u>+</u>	
() Abnormal Breast Cancer Screening Follow-Up	56.3%	90.0%	18	32	1	14	Ŧ	
(i) Colorectal Cancer Screening (CMS 130v10)	35.7%	66.0%	1,042	2,918	26	1,876	Ŧ	
(i) Abnormal FIT Follow-up Initiated	43.5%	100.0%	20	46	Demo	0 2 <b>1</b>	<b>↓</b>	

# Patient Visit Planning (PVP) Report



- User: Care Team Members
- Run Frequency: Daily
- Use Case: Supports morning huddles to prepare for the day's patients

2:40 PM Monday, June 13, 2022	Visit Re	eason: Hospital f/u from TCN for bleeding	esophageal varices.	. Admitted 6/7/2	22 and discharging 6/8/22. Apt made with nurse from TC
MOUSE, MICKEY MRN: DOB::	Sex at Birth: M GI: MALE SO: Straight	Phone: Lang: English Risk: Low (6)	Portal Access	e N	PCP: Payer: WORK COMP CM: Unassigned
DIAGNOSES (3)		ALERT	MESSAGE	DATE	RESULT
Cirrhosis Depress	sion SUD No Depend	Abnormal FIT Follow-Up	Overdue	6/7/2022	Fecal Occult Blood Test: Positive
RISK FACTORS (4)		HIV	Missing		
ASCVD Intermediate (17.67) BMI	SMI	_			
ТОВ					
SDOH (0)					
RAF GAPS DIAGNOSIS CATEGORIES (2)	)				
Substance abuse Gastro					
					Demo data

# **Open Lab Orders**

Open Lab Orders  MEASURE  FILTERS: April 2023 FOBT/FIT Lab Order  MEASURE ANALYZER	I≣ DETAIL LIST	<ul> <li>Filter to FIT and FOBT</li> <li>Labs</li> <li>Use Detail List to</li> </ul>
Metrics 29% 29% Apr 22	Comparison GROUP BY Order Type ~ 2ND N	
17 / 58 1 Exclusion(s) TARGET Create Target Apr 23 GROUP BY None ~ 🔅 😂	17 16 15	
50 45 40 39 35 30 25 20 18 18 18 18 12 12 13 12 12 13 12 12 13 12 13 12 12 13 12 13 12 13 12 13 12 13 12 13 12 13 12 13 14 15 15 15 15 15 15 15 15 15 15		

### **Pilot Gap Closure Dashboard**

White/Not Hispanic, Latino/a, or Spanish Origin

67%

2

Data Check In Report	t - Colorectal Cancer 👔	= FILTER	^	X
PERIOD	RENDERING PROVIDERS			
March 2024 V	All Rendering Provid_	+ Add Filter	<b>Y</b> Ø	Update

- 1 (

American Indian/Alaska Native/Not Hispanic, Latino/a, or Spanish Origin

Unreported/Choose Not to Disclose Race/Not Hispanic, Latino/a, or Spanish Origin

Black/African American/Not Hispanic, Latino/a, or Spanish Origin

More than One Race/Not Hispanic, Latino/a, or Spanish Origin

Other Asian/Not Hispanic, Latino/a, or Spanish Origin

White/Not Hispanic, Latino/a, or Spanish Origin

0.0%

35.7%

0.0%

54.5%

0.0%

55.6%

0

5

0

Demo

2

14

2

11

2

dafa

Colorectal Cancer Screening and Abnormal Follow	v-Up					<b>Open FIT Reminder APO Results</b>						Ŧ	Colorectal Cancer Screening Re	minder APO Resu	ults				Ŧ
March 2024						Q1 2024							Q1 2024						
♦ MEASURE	RESULT	🗢 NUM 🖨	DENOM 👙	🗧 EXCL 🌲	GAP	\$	MEASURE	RESULT	г 🗢 NUM 🖨	DENOM	EXCL 🔷	GAP	<b>\$</b>	MEASURE	RESULT	NUM	🗘 DENOM 🔶	EXCL	🔷 GAP
Colorectal Cancer Screening (CMS 130v12)	52.9%	200	378	6	178	APO Successfully Reached Enrollees		70.89	6 17	24	0	7	APO Successfully Reached Enrollees		74.3%	411	553	0	142
Abnormal FIT Follow-up	42.9%	3	7	0	4	APO Enrollees Who Made an Appointmen	nt	35.39	6 6	17	0	11	APO Enrollees Who Made an Appoin	tment	40.1%	165	411	0	246
						APO Enrollees Who Had an Encounter		5.99	i 1	17	0	16	APO Enrollees Who Had an Encount	er.	17.0%	70	411	0	341
						APO Care Gap Closure		41.29	5 7	17	0	10	APO Care Gap Closure		5.0%	33	660	0	627
								¢ (8											¢
Abnormal FIT Follow-Up by Ethnicity									C Screening by E	thnicity									Ŷ
March 2024									March 2024				🖨 RESUL						
♦ ETHNICITIES		<b>_</b>	RESULT	<b>V</b>	NUMER	ATOR 🗘 DENOMINAT			ETHNICITIES						NUMERATOR	<b>V</b>	DENOMINA		GAP
Another Hispanic, Latino/a, or Spanish Origin			50%			1	2		nother Hispanic, La	tino/a, or Spanish (	Drigin		44.9		44			98	54
Mexican, Mexican American, Chicano/a			0%			0	2		uban				66.7		2			3	1
Not Hispanic, Latino/a, or Spanish Origin			67%			2	3		lexican, Mexican An				60.5		52			86	34
								N	lot Hispanic, Latino/	a, or Spanish Origi	in		52.2	6	95			182	87
								L L	Inreported/Choose I	Not to Disclose Eth	nicity		77.8	6	7			9	2
Abnormal FIT Follow -Up by Race (Not Hispanic/La	atino)						Ŧ	¢ cr	C Screening by F	Race (Not Hispa	nic/Latino)								φĒ
March 2024									March 2024										
RACES AND ETHNICITIES		¢	RESULT	¢	NUME	RATOR 🗢 DENOMINAT	ror 🍦	GAP 🗳	RACES AND ETH	NICITIES				🗢 RES	ULT 🗢 N	UMERATOR	DENOM	INATOR 4	GAP



### A Closer Look at the Pilot Dashboard...

March 2023											
MEASURE	🔶 RESULT	🔶 NUM	🔶 DENOM	🔶 EXCL	🔷 GAP						
Colorectal Cancer Screening	39.5%	174	441	4	267						
Abnormal FIT Follow-up	100.0%	2	2	0	0						



### A Closer Look at the Pilot Dashboard...

Colorectal Cancer Screening Reminder APO Results										
Q1 2023										
MEASURE	RESULT	≑пим	DENOM	<b>≑</b> EXCL	<b>\$</b> GAP					
APO Successfully Reached Enrollees	61.3%	511	834	0	323					
APO Enrollees Who Made an Appointment	46.2%	236	511	0	275					
APO Enrollees Who Had an Encounter	12.9%	66	511	0	445					
APO Care Gap Closure	2.2%	13	599		586 2 M A					

<b>Open FIT Reminder APO Results</b>					
Q1 2023					
MEASURE	RESULT	¢num	DENOM	<b>⇔</b> EXCL	<b>\$</b> GAP
APO Successfully Reached Enrollees	53.1%	76	143	0	67
APO Enrollees Who Made an Appointment	77.6%	59	76	0	17
APO Enrollees Who Had an Encounter	17.1%	13	76	0	63
APO Care Gap Closure	20.4%	11	54	0	43
2818					



### A Closer Look at the Pilot Dashboard...

Abnormal FIT Follow-Up by Race/Ethnicity									
	NUM	DENOM	G A P						
100%	1	1	0						
100%	1	1	0						
	100%	100% 1	100% 1 1						

Abnormal FIT Follow-Up by Financial Class									
\$	RESULT	NUM	\$	DENOM	\$	GAP			
	100%	1		1		0			
	100%	1		1		0			
	\$	100%	100% 1	100% 1	100% 1 1	100% 1 1			

CRC Screening by Race/Ethnicity				
March 2023				
RACES AND ETHNICITIES	RESULT	♦ NUM	DENOM	🔶 G A P
American Indian/Alaska Native/Hispanic/Latino	0.0%	0	1	1
American Indian/Alaska Native/Non-Hispanic/Latino	100.0%	2	2	0
Asian/Non-Hispanic/Latino	44.4%	4	9	5
Black/African American/Non-Hispanic/Latino	37.5%	3	8	5
More than One Race/Hispanic/Latino	62.5%	15	24	9
More than One Race/Non-Hispanic/Latino	20.0%	1	5	4
Native Hawaiian/Non-Hispanic/Latino	100.0%	1	1	0
Unmapped/Hispanic/Latino	0.0%	0	6	6
Unmapped/Non-Hispanic/Latino	0.0%	0	18	18
Unreported/Refused to Report Race/Hispanic/Latino	60.0%	18	30	12
Unreported/Refused to Report Race/Non-Hispanic/Latino	66.7%	2	3	1
Unreported/Refused to Report Race/Unreported/Refused to Report Ethnicity	33.3%	1	3	2

Open FIT/FOBT Orders by Race			
March 2023			
RACES	RESULT	<b>\$</b> NUM	DENOM
American Indian/Alaska Native	100%	2	2
Asian	92%	11	12
Black/African American	83%	10	12
More than One Race	81%	13	16
Unreported/Refused to Report Race	71%		
White	77%	DGUP	000100

Abnormal FIT Follow-Up by Language									
March 2023									
LANGUAGES	🗢 RESULT	NUM	DENOM	🗢 🛛 GAP					
English	100%	2	2	0					

## Updated Dashboard + SDOH

Colorectal Cancer Sci DASHBOARD	reening Data Check in with SDOH 🕡	₹ FILTER	^	:
ERIOD	RENDERING PROVIDERS			_
March 2025 V	All Rendering Provid 🗸	+ Add Filter	T	🗘 Upd

#### CRC Screening & Abnormal FIT Follow-Up

March 2025

March 2025					
♦ MEASURE	🔷 RESULT	¢ NUM	DENOM	<b>♦ EXCL</b>	🔷 GAP
Colorectal Cancer Screening (CMS 130v12)	58.0%	102	176	2	74
Abnormal FIT Follow-up	50.0%	1	2	0	1

APO Campaign Res	sults: CRC Screening	Reminder				$\overline{\cdot}$
Q1 2025						
\$	MEASURE	🔷 RESULT	♦ NUM	DENOM	🗢 EXCL	🔷 GAP
APO Successfully Rea	ached Enrollees	69.2%	369	533	0	164
APO Enrollees Who M	1ade an Appointment	23.0%	85	369	0	284
APO Enrollees Who H	lad an Encounter	13.0%	48	369	0	321
APO Care Gap Closur	e	2.6%	15	572	0	557

#### APO Campaign Results: Open FIT Reminder

March 2025

Q1 2025					
♦ MEASURE	🔷 RESULT	¢ NUM	DENOM	<b>♦ EXCL</b>	🔷 GAP
APO Successfully Reached Enrollees	61.5%	8	13	0	5
APO Enrollees Who Made an Appointment	25.0%	2	8	0	6
APO Enrollees Who Had an Encounter	25.0%	2	8	0	6
APO Care Gap Closure	25.0%	2	8	0	6

ACTION RECOMMENDED: Outreach for Open FIT Orders (remind to complete)

#### Widgets Added

**= 0** 

ACTION NEEDED: Follow-Up on Abnormal FIT (has not been initiated)

Abnl FIT/FOBT F/U

|--|

🔷 AGE	🔷 RESULT	NUMERATOR	DENOMINATOR	🔷 🗛 GAP	

ACTION RECOMMENDED: FIT Outreach	ACTION RECOMMENDED: Target
to Patlents due for CRC Screen	FIT Outreach to 45-49yo Patients
March 2025	due for CRC Screen
<b>74</b> <sub>Colo</sub>	March 2025

#### **CRC Screening by Age**

March 2025				
<b>\$</b> AGE	RESULT	NUMERATOR	DENOMINATOR	🔷 🗛 GAP
45-49	57.9%	22	38	16
50-54	48.9%	22	45	23
55-59	59.0%	23	39	16
60-64	65.6%	21	32	11
65-69	58.3%	14	24	10
70-75	66.7%	10	15	5

ACTION RECOMMENDED: Targeted	
FIT Outreach to 45-49yo Patlents	Ŧ
due for CRC Screen	
March 2025	
16	
Colo	

= **o** 

#### **= 0 Open FIT Orders by Age** March 2025 45-49 24 67% 36 50-75 74% 73 90 76+ 75% 3

101

Open orders



Ŧ

### Widgets Modified

Abnormal FIT Follow-Up by Ethnic	14			0	CRC Screening by Ethnicity				ö	Open FIT Orders by Ethnicity = 🗧					
March 2025			*	March 2025					March 2025						
			DENOMINATOR	A CAP				DENOMINATOR	A CAP				ORDERED LABS		
Another Hispanic, Latino/a, or	V NESOEI	<b>WIGHLINGTON</b>	VERGINIATOR	<b>U</b>	Another Hispanic, Latino/a, or	TRESOLT	NOPLEATON	DENOMINATOR		Another Hispanic, Latino/a, or Spanish Origin	71%	20	28		
Spanish Origin	100%	1	1	0	Spanish Origin	55.2%	32	58	26	Cuban	100%	20	20		
Cuban	0%	0	1	1	Cuban	75.0%	3	4	1	Mexican, Mexican American, Chicano/a	54%	7	13		
					Mexican, Mexican American, Chicano/a	56.8%	21	37	16	Not Hispanic, Latino/a, or Spanish Origin	74%	72	97		
					Not Hispanic, Latino/a, or Spanish Origin	62.9%	56	89	33 🖉						
Abnormal FIT Follow-Up by Race (	Not Hispani	c/Latino)	=	¢ T	CRC Screening by Race (Not His	panic/Latino)	)		Ξ¢	Open FIT Orders by Race (Not Hispanic/La	tino)		<b>≂ ¢</b>		
March 2025					March 2025					March 2025					
	RESULT 🔶	NUMERATOR	DENOMINATOR	🔷 GAP	RACES AND ETHNICITIES	🔷 RESULT	NUMERATOR	DENOMINATOR	<b>⇔</b> GAP			🗢 OPEN			
					American Indian/Alaska Native/Not Hispanic, Latino/a, or Spanish Origin	100.0%	2	2	0	RACES AND ETHNICITIES Black/African American/Not Hispanic, Latino/a, c	+ RESUL				
					Black/African American/Not Hispanic, Latino/a, or Spanish Origin	45.5%	5	11	6	Spanish Origin Other Asian/Not Hispanic, Latino/a, or Spanish	100				
					Other Asian/Not Hispanic, Latino/a, or Spanish Origin	50.0%	1	2	1	Origin White/Not Hispanic, Latino/a, or Spanish Origin	72		4 5 90		
					Unreported/Choose Not to Disclose Race/Not Hispanic, Latino/a, or Spanish Origin	100.0%	2	2	0						
					White/Not Hispanic, Latino/a, or Spanish Origin	63.9%	46	72	26						
								·							
Abnormal FIT Follow-Up by Financ	cial Class			¢	CRC Screening by Financial Clas	is			0	Open FIT Orders by Financial Class			÷¢		
March 2025					March 2025					March 2025					
🗢 UDS FINANCIAL CLASSES	RESULT	NUMERATOR	DENOMINATOR	🔷 GAP	<b>\$ UDS FINANCIAL CLASSES</b>	🔷 RESULT	NUMERATOR	DENOMINATOR	🔷 GAP	🔷 UDS FINANCIAL CLASSES 🛛 💠 R	ESULT 🔶	OPEN ORDERS	ORDERED LABS		
Dual Eligible Medicare and Medicaid	0%	0	1	1	Dual Eligible Medicare and Medicaid	<b>76.2%</b>	16	21	5	Dual Eligible Medicare and Medicaid	50%	1	2		
Medicaid	100%	1	1	0	Medicaid	54.0%	27	50	23	Medicaid	100%	4	4		
Medicare	0%	0	1	1	Medicare	76.9%	30	39	9	Medicare	7.61				
					Deiuste Insurance	(2.2%)			20	Daiusta la usa as	100%	12	12		

											~			
Abnormal FIT Follow	Abnormal FIT Follow-Up by Language					CRC Screening by	Language			÷.	Open FIT Orders by L	anguage		φ
March 2025						March 2025					March 2025			
🔷 LANGUAGES	🔷 RESULT 🖨	NUMERATOR	DENON	MINATOR	🔷 GAP	LANGUAGES	🔷 RESULT	NUMERATOR	DENOMINATOR	🔷 GAP	🔷 LANGUAGES	🔷 RESULT	OPEN ORDERS	ORDERED LABS
Spanish	50%	1		2	1	Dari	0.0%	0	1	1	English	74%	75	102
						English	62.8%	59	94	35	French/Creole	100%	1	1
						French/Creole	0.0%	0	1	1	Mandarin	100%	1	1
						Kinyarwanda	0.0%	0	1	1	Spanish	67%	24	36
						Spanish	54.3%	51	94	43				
						Vietnamese	100.0%	1	1	0				
						Yoruba	100.0%	1	1	0				

### Widgets Added

Abnormal FIT Follow-Up by SDOH (with at least 1 SDOH)				÷	0
March 2025					
⇔sdoн	🔷 RESULT	NUMERATOR	DENOMINATOR	\$	GAP
FPL<200	100%	1	1		0
HISP/LAT	50%	1	2		1
LANGUAGE	50%	1	2		1
RACE	0%	0	1		1

CRC Screening by SDOH (with at least 1 SDOH)				$\equiv 0$
March 2025				
<b>\$</b> SDOH	RESULT	NUMERATOR	DENOMINATOR	🔷 🗛 GAP
FPL<200	58.2%	82	141	59
HISP/LAT	56.0%	56	100	44
HOMELESS	44.4%	4	9	5
INSURANCE	30.0%	9	30	21
ISOLATION	20.0%	1	5	4
LANGUAGE	53.5%	53	99	46
RACE	50.0%	20	40	20

Open FIT Orders by	÷ 🗘		
March 2025			
<b>\$</b> SDOH	🔶 RESULT	OPEN ORDERS	ORDERED LABS
FPL<200	62%	24	39
HISP/LAT	65%	24	37
INSURANCE	57%	8	14
ISOLATION	100%	1	1
LANGUAGE	67%	24	36
RACE	71%	5	7

### Demo data

### **Tools to Close Cancer Screening Gaps**

**Goal:** Develop & pilot test **new tools in DRVS** that may help CHCs more easily track and address care caps for patients in need of **diagnostic follow-up of an abnormal cancer screening**.



### **New DRVS Tools**

Abnormal follow-up measures Abnormal follow-up point-of-care alerts Open lab orders measure Screening and abnormal follow-up gap closure dashboard



### **Tools to Close Cancer Screening Gaps**

**Goal:** Develop & pilot test **new tools in DRVS** that may help CHCs more easily track and address care caps for patients in need of diagnostic follow-up of an abnormal cancer screening.




------

### **New DRVS Tools**


Abnormal follow-up measures Abnormal follow-up point-of-care alerts Open lab orders measure Screening and abnormal follow-up gap closure dashboard **External Practice** Facilitation

(coaching and support)



## Findings Clinical Outcomes


Diagnostic Follow-Up Completion by Screening Type and Timepoint



Abnormal Mammogram Follow-Up

Diagnostic follow-up for both screening types **improved significantly** at all three timepoints.

# Findings | Clinical Outcomes



Screening completion for both cancer sites improved significantly.

### Findings | Implementation Outcomes

### **Online Survey**

Tools and facilitation: Highly acceptable, appropriate, and feasible.

#### **Qualitative Interviews**

- **Tools:** Well-designed, easy to use, and an advantage over existing tools/previous practices.
  - Gap closure dashboard highlighted as an important value-add
- **Facilitation:** Well-thought-out, structured, and designed; not complicated; and supported tool integration.



# **CHC** Partnership

0

## **CHC** Partner Perspective

## Experiences

## Sustainment

## Next Steps



## Coastal Family Health Center (CFHC)



### FQHC in South Mississippi

 13 stand-alone clinics, 1 mobile unit, 5 pharmacies, & 23 schools

 36,000+ patients served annually; over 110,000 visits

Size

Family and internal medicine, pediatrics, psychiatry/behavioral health, lab, radiology (including 3D mammography), & social services Ryan White and Healthcare for the Homeless Programs

**Specialties** 

Special Populations

Patient-Centered Medical Home & Joint Commission Accredited for Ambulatory & Behavioral Health

## CFHC | Overcoming Challenges in Cancer Screening & Follow-Up

#### **CFHC & Clinical Quality Measure**

• Responsible for breast, colorectal and cervical cancer screening.

**Challenges in Cancer Screening & Follow-Up** 

• Struggled to improve cancer screening and abnormal follow-up rates.

#### **DRVS Implementation (2019)**

• Initial improvement in screening rates, but still not maximized for significant outcomes.

Measure	Goal	2020 Outcome
Colorectal Cancer Screening	30%	21.31%
Breast Cancer Screening	50%	26.57%

### **Partnership with ISCCCE & Azara**

### Tools to Close Screening Gaps Pilot

- Collaboration with ISCCCE & Azara provided knowledge & resources.
- Helped optimize Azara for colorectal & breast cancer screening and follow-up.




### **Key Project Support**

- Developed dashboards, scorecards & alerts for tracking.
- Mapped workflows for real-world clinical integration.
- Engaged provider/nurse teams to enhance patient care.
- Leveraged APO for outreach & FIT FOBT follow-ups.
- Designed PDSA for FIT FOBT mail-back process with CHWs.

## **CFHC | Project Successes**

#### **Percentage Increase**



# **Next Steps**



## **Next Steps for CFHC**

#### Enhancing Colorectal Cancer Screening

Integrated Cologuard into NextGen for improved screening rates.

### Strengthening Data Accuracy

- Implemented ongoing data hygiene program.
- Leveraging Azara's data validation tools with HCCN/PCA support.

Measure	Goal	2020 Outcome	2024 Outcome
Colorectal Cancer Screening	30%	21.31%	27.1%
Breast Cancer Screening	50%	26.57%	47.7%

# Next Steps for ISCCCE



#### **ONGOING RESEARCH & COLLABORATION**

Active: Optimized Cancer Screening & Follow-up Tools + New Tobacco Cessation Tools + Community Engagement Strategies

#### Pending:

**CRC Screening & Follow-up Tools** 

Patient Outreach Strategies (Optimized APO)

SCALE UP

### Abnormal Follow-up Suite of Tools <u>Available as Add-On</u>

### Thank You for Your Attention!

Lynn Ibekwe-Agunanna, PhD, MPH Assistant Professor | UT Southwestern Medical Center Lynn.Ibekwe-Agunanna@UTSouthwestern.edu

Stacey Coleman, MPH Director of Quality Management | Coastal Family Health Center Scurry@Coastalfamilyhealth.org

For questions about Azara & DRVS please contact:

**Emma Knapp, MPH, PCMH-CCE** Sr. Clinical Improvement Specialist | Azara Healthcare <u>Emma.knapp@azarahealthcare.com</u>






# Questions?



## We want to hear from you!

Click on the session from your agenda in the conference app. Click the stars in the center of your screen to rate and provide feedback.



Quick and Easy

Rate the session and the speaker(s)



Provide brief feedback or ideas



Help us continue to improve

## Achieve, Celebrate, Engage!

# ACE'd it? Share your DRVS success story and become an Azara ACE!

Show your organization has used DRVS to Achieve measurable results, Celebrate improvement in patient health outcomes, and effectively Engage care teams and/or patients. Stories should showcase how DRVS helped your organization overcome a challenge, the tools and solutions used to drive improvement and details of the successes that resulted from your initiatives. ACEs should be able to provide examples that quantify quality improvement, cost savings, operational efficiency or patient health improvement.

#### **Benefits:**

- Azara will help tell your story and provide a client-branded version for your use
- Potential to create a 2-4 minute video or hour-long Azara-hosted webinar
- Potential to be featured at next year's Azara User Conference
- Win Azara swag!

Submit your success story by completing the form at this link.







# Thanks for attending!